RxDoctor Payments Data

Hilary Frank, DO

Obstetrics & Gynecology · Maple Grove, MNNPI 1952716680

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Axonics, Inc. at 59.0% of the total. Reporting peaked in 2023 at $3,280 and has fallen 95.7% since, to $141 in 2025. Among obstetrics & gynecology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,292in general payments, 2019–2025

Across 86 payments — averaging $84.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$4K
  • Valencia Technologies Corporation$1K
  • Boston Scientific$913
  • Medtronic$664
  • Coopersurgical, Inc.$247
  • AbbVie$41
  • plus $112 from 6 others
$650in research payments, 2019–2025

Across 1 payment — averaging $650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$650

What the payments were for

  • Travel & lodging$2,99941%
  • Food & beverage$4,29359%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,292 in reported general payments places this provider in the 95th percentile of 615 obstetrics & gynecology providers in Minnesota.

See all obstetrics & gynecology providers in Minnesota

Medicare billing

Part B allowed, 2024
$26,264
Medicare patients
66
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron32$30,960
GemtesaVibegron19$19,632
Estradiol58$4,501
Clobetasol Propionate18$330
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$85
Oxycodone Hcl31$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$20$30,96032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 obstetrics & gynecology providers in Minnesota.

Other obstetrics & gynecology in Maple Grove

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →